Cardiovascular Outcomes and Angiotensin Converting Enzyme Inhibitors: Beyond Blood Pressure Control: Editorial to: “Secondary Prevention of Coronary Disease with ACE Inhibition—Does Blood Pressure Reduction with Perindopril Explain the Benefits in EUROPA?” by Remme et al.

By Verma Anil   Ventura Hector  

Cardiovascular Drugs and Therapy, Vol. 23, Iss. 2, 2009-04 ,pp. : 109-111

Springer Publishing Company

Access to resources Recommend Favorite

Implementation of Cardiovascular Disease Prevention Guidelines into Clinical Practice: an Unmet Challenge?

By  

Current Pharmaceutical Design, Vol. 21, Iss. 9, 2015-03 ,pp. : 1180-1184

Bentham Science Publishers

Access to resources Recommend Favorite

Secondary Prevention of CAD with ACE Inhibitors: A Struggle Between Life and Death of the Endothelium

By Ferrari Roberto   Guardigli Gabriele   Ceconi Claudio  

Cardiovascular Drugs and Therapy, Vol. 24, Iss. 4, 2010-08 ,pp. : 331-339

Springer Publishing Company

Access to resources Recommend Favorite

The clinical and economic impact of a secondary heart disease prevention clinic jointly implemented by a practice nurse and pharmacist

By Reilly V.   Cavanagh M.  

Pharmacy World and Science, Vol. 25, Iss. 6, 2003-12 ,pp. : 294-298

Springer Publishing Company

Access to resources Recommend Favorite

The Role of AGEs and AGE Inhibitors in Diabetic Cardiovascular Disease

By  

Current Drug Targets, Vol. 6, Iss. 4, 2005-06 ,pp. : 453-474

Bentham Science Publishers

Access to resources Recommend Favorite